Lopressor® / Toprol-XL®
Metoprolol Tartrate / Succinate
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$40
With Insurance
$4-10
Supplement Questions
FDA Black Box Warning
ABRUPT WITHDRAWAL
Abrupt discontinuation in patients with coronary artery disease has caused angina exacerbation, myocardial infarction, and death. Taper over 1–2 weeks and monitor carefully.
Strict Contraindications
How It Works
Metoprolol is a beta-1 selective adrenergic blocker. It competes with epinephrine (adrenaline) and norepinephrine at beta-1 receptors — primarily in the heart — blocking their stimulating effects. The result is a slower, less forceful heartbeat and lower blood pressure. The "beta-1 selective" part means it targets the heart more than the lungs, making it safer than older, non-selective beta blockers in patients with mild asthma (though not risk-free).
Why the side effects happen
Because beta-1 receptors also exist in the eyes (fluid pressure), pancreas (insulin response), and peripheral blood vessels, blockade causes cold extremities, blunted blood sugar warning signs, and fatigue. The drug's lipid solubility means it crosses the blood-brain barrier — explaining vivid dreams, sleep disturbance, and depression reported by some patients. The exercise tolerance reduction is direct: beta blockade caps the maximum heart rate, limiting cardiac output during intense exertion.
When Will I Feel It?
Heart rate slowing begins within hours of the first dose. Blood pressure reduction builds over days to weeks as renin suppression and vascular effects accumulate.
Heart rate reduction begins. Resting HR typically drops 5–15 bpm with first dose. Dizziness is common in the first hours — do not drive until you know how it affects you.
Blood pressure begins falling as renin suppression accumulates. Fatigue and cold extremities may peak this week. Most patients adjust within 2–4 weeks.
Full antihypertensive effect established. Heart failure patients typically see symptom improvement (less shortness of breath, improved exercise tolerance) in this window.
Cardiac remodeling benefits become apparent in heart failure. Ongoing monitoring of resting heart rate and blood pressure guides dose optimization.
Adherence Note
Consistency is critical with metoprolol — missed doses allow sympathetic rebound, especially in patients with coronary artery disease. Take at the same time daily. The extended-release (succinate) formulation is once-daily and shows more consistent 24-hour coverage than the twice-daily tartrate formulation.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Fatigue / tiredness
10-15%Most common complaint; often improves after a few weeks. Morning dosing may help.
Dizziness / lightheadedness
10%Rise slowly from sitting. Worse in first weeks.
Bradycardia (slow heart rate)
10%Contact your doctor if resting heart rate falls below 50 bpm.
Cold hands and feet
8%Beta blockers reduce blood flow to extremities. Layering helps; Raynaud's patients should discuss alternatives.
Shortness of breath
5%Report immediately — can indicate bronchospasm, especially in asthma.
Sleep disturbance / vivid dreams
5-10%More common with lipid-soluble beta blockers like metoprolol. Taking in morning may help.
Weight gain
5-7%Beta blockers slow metabolism slightly and blunt exercise heart rate — combine with dietary awareness.
Depression / mood changes
3-5%Tell your doctor. Switching to a less lipid-soluble beta blocker (atenolol) may help.
Impaired exercise tolerance
CommonBeta blockers cap maximum heart rate. Do not use heart rate as an exercise intensity guide — use perceived exertion instead.
Sexual dysfunction
3-5%More common in men. Often underreported. Tell your doctor — alternatives exist.
Serious Adverse Effects
- • Bronchospasm (dangerous in asthma/COPD)
- • Heart block (electrical conduction failure)
- • Acute heart failure decompensation
- • Rebound hypertension / angina on abrupt cessation
- • Masking of hypoglycemia in diabetics
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Bronchospasm (dangerous in asthma/COPD)
- Heart block (electrical conduction failure)
- Acute heart failure decompensation
- Rebound hypertension / angina on abrupt cessation
- Chest pain or tightness
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Category C. Associated with fetal growth restriction and bradycardia. Used when benefit outweighs risk (e.g., pre-eclampsia management). Monitor fetal growth.
Passes into breast milk at low levels. Monitor infant for bradycardia.
Estrogen loss post-menopause may raise blood pressure and increase fatigue independently of other factors. Some of the side effects of metoprolol — fatigue, weight changes, reduced exercise tolerance — can overlap with common menopause symptoms. A full picture of cardiovascular and hormonal health may help your doctor tailor your care plan.
Used off-label for pediatric hypertension and arrhythmias. Dose by weight.
Greater sensitivity to bradycardia. Start at 25mg. Monitor resting heart rate closely.
Primarily hepatically metabolized. Renal impairment does not significantly affect dosing.
Hepatic metabolism is impaired in cirrhosis. Reduce dose and monitor closely.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Lifestyle Approaches for Blood Pressure & Heart Rate
Weight loss, alcohol reduction, and eliminating ultra-processed foods appear to be among the most potent lifestyle levers for blood pressure. The evidence on these approaches has strengthened considerably since the 1997 DASH trial, which has often been oversimplified as "reduce sodium and fat."
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Weight loss
Obesity and excess visceral fat drive hypertension through insulin resistance, leptin signaling, and sustained sympathetic nervous system activation — independent of sodium intake. This is the most consistently evidenced lifestyle intervention across all BP medications.
Approximately −1 mmHg systolic per kg lost; larger reductions in those with significant excess weight
Eliminating ultra-processed foods
Ultra-processed foods raise blood pressure through multiple simultaneous pathways: seed oil-driven vascular inflammation, refined carbohydrate-driven insulin resistance, and excess fructose driving uric acid and endothelial dysfunction. Whole-food diets consistently outperform low-sodium processed food diets for BP outcomes.
Observational data and whole-food intervention studies suggest significant BP benefit beyond what sodium restriction alone achieves
Alcohol reduction
Alcohol raises blood pressure in a dose-dependent, consistent way. Even moderate intake (2+ drinks/day) measurably elevates systolic BP. Alcohol reduction is one of the most underappreciated and immediately modifiable levers — and particularly relevant given metoprolol's additive effect on heart rate lowering.
−4 to −7 mmHg systolic with reduction from moderate to low or no intake
Reducing refined carbohydrates and added sugar
Hyperinsulinemia — driven by refined carbs and added sugar — causes renal sodium and water retention through insulin's direct action on kidney tubules, and activates the sympathetic nervous system. This mechanism may contribute more to elevated BP in many patients than dietary sodium per se.
Low-carbohydrate dietary interventions show systolic BP reductions of 4–10 mmHg across multiple trials
Aerobic exercise
Sustained aerobic training lowers resting heart rate and systolic BP via cardiac remodeling, improved vagal tone, and reduced sympathetic activity — mechanisms that overlap beneficially with metoprolol's beta-blockade. Exercise also reduces cardiovascular mortality independently of BP numbers.
−5–8 mmHg systolic; −5–10 bpm resting heart rate; 20–30% reduction in cardiovascular mortality
Potassium and magnesium from food
High dietary potassium (vegetables, legumes, fruit) lowers BP by promoting renal sodium excretion. Magnesium (leafy greens, nuts, seeds) supports vascular smooth muscle relaxation. These nutrients — not sodium restriction — may account for much of the DASH trial's documented effect. Getting them from whole food sources is more effective than supplementation for most people.
Potassium-rich diets associated with −3 to −5 mmHg systolic; magnesium may contribute an additional 4–5 mmHg in deficient individuals
Slow breathing / HRV training
Paced breathing at approximately 6 breaths per minute activates the baroreceptor reflex and improves heart rate variability. Particularly relevant alongside a beta blocker, which already blunts sympathetic tone — the two approaches may work through complementary autonomic pathways.
Several RCTs show −5–10 mmHg systolic; evidence base is smaller than for diet and exercise
Key Studies
How It Compares
Beta blockers are second-line for uncomplicated hypertension per most current guidelines (after ACE inhibitors/ARBs and calcium channel blockers), but remain first-line when hypertension accompanies heart failure, angina, post-MI, or atrial fibrillation.
Strengths
- Strong evidence for mortality reduction in systolic heart failure (MERIT-HF: −34% all-cause mortality)
- Effective for rate control in atrial fibrillation
- Reduces angina frequency and severity
- Prevents sudden cardiac death post-MI
- Inexpensive generic — under $20/month
- Can be used for migraine prevention (off-label)
Weaknesses
- Not recommended as first-line for uncomplicated hypertension (UK NICE, ESC guidelines)
- Worsens fatigue, weight gain, and exercise tolerance
- Blunts hypoglycemia warning signs in diabetics
- Contraindicated or risky in asthma/COPD (bronchospasm risk)
- Cannot be stopped abruptly — dangerous rebound in CAD patients
- Depression and sexual dysfunction underreported
Clinically Preferred Alternatives
Global Prescribing & Pricing
Beta blockers are used globally for hypertension and heart failure; prescribing philosophy varies significantly by country
United States
$15–30/mo
#1 beta blocker in the US; often first-line for hypertension with heart failure or angina
No lifestyle prerequisite required before prescribing
Usually covered as generic
United Kingdom
~$2–5/mo
NICE no longer recommends beta blockers as first-line for hypertension without compelling indication
Preferred only when ACE inhibitors are not tolerated or patient has angina/heart failure
Covered by NHS
Germany
~$5–12/mo
Widely used; carvedilol increasingly preferred for heart failure
Lifestyle counseling emphasized; structured cardiac rehabilitation programs common
Covered by GKV
Sweden
~$4–8/mo
Home of original metoprolol development (Astra AB); high prescribing rate
Exercise programs heavily subsidized alongside pharmacotherapy
Covered by landsting
Japan
~$8–18/mo
Carvedilol preferred over metoprolol for heart failure in Japanese guidelines
Lower dose protocols; lifestyle modification programs widely prescribed alongside
Covered by JHIS
The UK and most European guidelines have de-emphasized beta blockers as first-line for uncomplicated hypertension — they are now reserved for hypertension with a specific heart condition. The US still uses them more broadly. The same generic metoprolol costs $15–30/month in the US vs $2–5 in the UK.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
MERIT-HF was funded by AstraZeneca (then Astra AB), who manufactured metoprolol succinate. COMMIT was a large independent Chinese trial co-sponsored by government and academic institutions. Key investigators in MERIT-HF received research grants and speaking fees from Astra AB.
Declared Conflicts of Interest
MERIT-HF principal investigators had declared financial relationships with Astra AB. The trial contributed significantly to metoprolol succinate becoming standard of care for heart failure, a multi-billion dollar market. COMMIT was more independently funded but conducted in a different patient population (acute MI in Chinese patients).
Key Efficacy Results
MERIT-HF: 34% reduction in all-cause mortality in heart failure; COMMIT: No survival benefit and increased cardiogenic shock in acute MI patients
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Metoprolol Tartrate / Succinate. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Metoprolol Tartrate / Succinate in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| MERIT-HF (AstraZeneca) | PMID:10376614 | |
| COMMIT (Acute MI) | NCT00222755 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Abrupt discontinuation in patients with coronary artery disease (CAD) has caused angina, myocardial infarction, and sudden cardiac death due to beta-receptor upregulation during chronic use. Even in patients without known CAD, rebound tachycardia and hypertension can be dangerous.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research and clinical guidelines document that abrupt discontinuation carries serious cardiac risk — stopping under medical supervision is documented as essential
- ·Published protocols describe reducing by 50% every 1–2 weeks (e.g., 100mg → 50mg → 25mg → stop)
- ·Research recommends monitoring heart rate and blood pressure twice daily throughout the stopping process
- ·Research supports building a lifestyle foundation (reducing ultra-processed foods, refined carbs, alcohol; increasing aerobic exercise) before stopping
- ·Published guidelines emphasize that surgical teams should be informed before stopping metoprolol — sudden cessation before surgery carries documented cardiac risk
Warning Symptoms — Contact Your Doctor If You Experience:
- Chest pain or tightness
- Heart rate above 100 bpm at rest
- Blood pressure rising above 150/90
- Shortness of breath or palpitations
- Sweating at rest
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.What is the primary reason a beta blocker is recommended for me — is it hypertension, heart failure, angina, atrial fibrillation, or another indication?
- 2.What is my resting heart rate target on this medication?
- 3.How will this affect my exercise routine — should I use perceived exertion instead of heart rate?
- 4.If I'm diabetic, how will I recognize a low blood sugar episode on this medication?
- 5.What is the plan for tapering if I ever need to stop?
Lab Tests to Request
- Resting heart rate
- Blood pressure log
- EKG (baseline)
- Fasting glucose (if diabetic)
- Liver function (hepatic metabolism)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Lopressor® / Toprol-XL®
- What is Lopressor® / Toprol-XL® used for?
- Lopressor® / Toprol-XL® (Metoprolol Tartrate / Succinate) is a Beta-1 Selective Blocker manufactured by Generic / AstraZeneca. FDA-approved indications include: Hypertension; Angina pectoris; Heart failure (succinate only); Post-heart attack; Atrial fibrillation (rate control); Migraine prevention.
- What are the common side effects of Lopressor® / Toprol-XL®?
- Common side effects of Lopressor® / Toprol-XL® include: Fatigue / tiredness (10-15%); Dizziness / lightheadedness (10%); Bradycardia (slow heart rate) (10%); Cold hands and feet (8%); Shortness of breath (5%).
- How much does Lopressor® / Toprol-XL® cost?
- Lopressor® / Toprol-XL® list price is approximately $40. With insurance it typically costs $4-10; without insurance approximately $15-30.
- Who funded the clinical trials for Lopressor® / Toprol-XL®?
- MERIT-HF was funded by AstraZeneca (then Astra AB), who manufactured metoprolol succinate. COMMIT was a large independent Chinese trial co-sponsored by government and academic institutions. Key investigators in MERIT-HF received research grants and speaking fees from Astra AB.
- How strong is the clinical evidence for Lopressor® / Toprol-XL®?
- Key studies: MERIT-HF, COMMIT, MAPHY. MERIT-HF: 34% reduction in all-cause mortality in heart failure; COMMIT: No survival benefit and increased cardiogenic shock in acute MI patients Potential conflicts of interest: MERIT-HF principal investigators had declared financial relationships with Astra AB. The trial contributed significantly to metoprolol succinate becoming standard of care for heart failure, a multi-bi.
- Are there non-drug alternatives to Lopressor® / Toprol-XL®?
- Weight loss, alcohol reduction, and eliminating ultra-processed foods appear to be among the most potent lifestyle levers for blood pressure. The evidence on these approaches has strengthened considerably since the 1997 DASH trial, which has often been oversimplified as "reduce sodium and fat." See the Alternatives tab for full details.
Get notified when we update Lopressor® / Toprol-XL®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.